Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: WHAT THE READER WILL GAIN: AFFIRM and SENTINEL showed improvements in progression of MS. ENACT-1 failed to show a significant effect, but the follow-up trials ENACT-2 and ENCORE were able to demonstrate a response to natalizumab. TAKE HOME MESSAGE: Two trials on efficacy of Tysabri for treatment of MS demonstrated positive results. Efficacy for CD was mixed. More research demonstrating head-to-head evidence against other agents is necessary to determine if Tysabri's benefits are significant.
|
Authors | Ashley Bivins, Karolyn Hou, Nana Ayesu, Brian Ellsworth Jr, Susan Montenegro, Xiao Tu, Cynthia Boyle, Thomas Dowling, Fadia T Shaya |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 10
Issue 8
Pg. 1279-87
(Aug 2010)
ISSN: 1744-7682 [Electronic] England |
PMID | 20626228
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
- Natalizumab
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Clinical Trials as Topic
- Crohn Disease
(drug therapy)
- Evidence-Based Medicine
- Formularies as Topic
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy)
- Natalizumab
- Treatment Outcome
|